Ind Swift

Research & Development

Our R&D centre is recognised by the Government of India's Ministry of Science & Technology.
Taste masking (Coated granulation) technology in macrolides, especially in Clarithromycin, Azithromycin and Roxithromycin.
A grant of US patent for Development of non infringing process for Clarithromycin dispersible tablets and Clarithromycin- Once a day, a controlled release formulation completely developed in-house at its R&D centre.
Developing of different Nitazoxanide dosage forms.
Development of Fexofenadine (latest antiallergic) dispersible tablets and ready to file patent for the same.
Sustained release form of Isoxsuprine HCl.
Mouth dissolving tablet of Betamethasone.
Development of tablet in tablet technology.
3 patents for APIs for non infringing processes filed.
A new separate wing in Herbal extract.

Manufacturing

All the manufacturing units are designed to comply with current stringent GMP norms as proposed by world regulatory bodies like USFDA, MHRA, EU, and WHO, and accreditations from ISO 14000

Ind-Swift is known as one of the biggest global bulk producers of APIs like clarithromycin, fexofenadine, atorvastatin etc. (For details visit our group company’s website Ind-Swift Labs Limited.)

Launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia.

Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials

Financial (2003-04)

Reported a TSR of Rs. 41.79 cr –more than meeting the shareholders expectations.

Maintained our per share earning on a 40 per cent enhanced equity base.

EBIDTA margins grew by 107 basis points to 11.77 per cent.

Revenues grew by 19.61 per cent

The net profit growth of 26.20 percent outperformed our revenue increase.